Skip to content
10-Q

Quarterly Report

ANAVEX LIFE SCIENCES CORP. AVXL

0001731122-25-000724

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · May 13, 2025 85.37M sh
Shares Diluted Q2 2025 · Mar 31, 2025 85.07M sh
Shares Diluted Q2 2025 · Mar 31, 2025 84.94M sh
Shares Diluted Q2 2025 · Mar 31, 2024 82.46M sh
Shares Diluted Q2 2025 · Mar 31, 2024 82.27M sh
Operating Cash Flow Q2 2025 · Mar 31, 2025 −$17.98M
Operating Cash Flow Q2 2025 · Mar 31, 2024 −$18.97M
Cash And Equivalents Q2 2025 · Mar 31, 2025 $115.77M
Cash And Equivalents Q2 2025 · Sep 30, 2024 $132.19M
Stockholders Equity Q2 2025 · Mar 31, 2025 $99.76M
Stockholders Equity Q2 2025 · Dec 31, 2024 $110.92M
Stockholders Equity Q2 2025 · Sep 30, 2024 $120.26M
Stockholders Equity Q2 2025 · Mar 31, 2024 $134.96M
Stockholders Equity Q2 2025 · Dec 31, 2023 $135.58M
Stockholders Equity Q2 2025 · Sep 30, 2023 $141.85M
Total Liabilities Q2 2025 · Mar 31, 2025 $17.38M
Total Liabilities Q2 2025 · Sep 30, 2024 $15.3M
Total Assets Q2 2025 · Mar 31, 2025 $117.14M
Total Assets Q2 2025 · Sep 30, 2024 $135.57M
Eps Diluted Q2 2025 · Mar 31, 2025 −$0.13
Eps Diluted Q2 2025 · Mar 31, 2025 −$0.27
Eps Diluted Q2 2025 · Mar 31, 2024 −$0.13
Eps Diluted Q2 2025 · Mar 31, 2024 −$0.23
Eps Basic Q2 2025 · Mar 31, 2025 −$0.13
Eps Basic Q2 2025 · Mar 31, 2025 −$0.27
Eps Basic Q2 2025 · Mar 31, 2024 −$0.13
Eps Basic Q2 2025 · Mar 31, 2024 −$0.23
Rd Expense Q2 2025 · Mar 31, 2025 $9.89M
Rd Expense Q2 2025 · Mar 31, 2025 $20.34M
Rd Expense Q2 2025 · Mar 31, 2024 $9.73M
Rd Expense Q2 2025 · Mar 31, 2024 $18.41M
Net Income Q2 2025 · Mar 31, 2025 −$11.2M
Net Income Q2 2025 · Mar 31, 2025 −$23.31M
Net Income Q2 2025 · Mar 31, 2024 −$10.55M
Net Income Q2 2025 · Mar 31, 2024 −$19.17M
Operating Income Q2 2025 · Mar 31, 2025 −$12.51M
Operating Income Q2 2025 · Mar 31, 2025 −$26.11M
Operating Income restated Q2 2025 · Mar 31, 2024 −$12.62M
Operating Income restated Q2 2025 · Mar 31, 2024 −$24M